Sanofi to build new facility in Canada to increase global
availability of high-dose influenza vaccine
Sanofi to build new facility in Canada
to increase global availability of high-dose influenza
vaccine
- Sanofi announces investment of more than €600 million to build
a new vaccine facility in Toronto to increase supply of its
differentiated influenza vaccines in Canada, the United States and
Europe
- In partnership with the Governments of Canada and Ontario, and
the City of Toronto, the new facility will also enhance influenza
pandemic preparedness efforts
- Fluzone® High-Dose Quadrivalent influenza vaccine has four
times more antigen than standard-dose vaccine and is specifically
designed to provide superior protection against influenza for older
adultsi
PARIS – March 31, 2021 – Sanofi
today announced an investment of more than €600 million in a new
vaccine manufacturing facility at its existing site in Toronto,
Canada. The investment in a new facility will provide additional
antigen and filling capacity for Sanofi’s Fluzone® High-Dose
Quadrivalent influenza vaccine, helping to increase supply
availability in Canada, the United States and Europe.
“As a leading vaccines Company, we continuously
look ahead to address the fast-growing demand for those influenza
vaccines that have demonstrated clinical superiority against
standard-dose vaccines. Fluzone High-Dose provides a long-term
competitive advantage and this new investment will ensure more
seniors around the world are better protected against influenza and
its complications. In addition, it will be a key resource to assist
against future pandemics,” said Paul Hudson, Chief Executive
Officer, Sanofi. “We welcome the ongoing partnership with the
Canadian authorities, who supported us to make today’s great news a
reality; this will make the country, which has a strong legacy in
vaccines research and development, one of our key hubs in our
effort to protect and improve human health across the globe.”
François-Philippe Champagne, Minister of
Innovation, Science and Industry said, “Today’s announcement
demonstrates Canada’s ability to attract foreign investment and to
develop facilities with made-in-Canada solutions. This
once-in-a-generation investment shows our government’s commitment
to rebuilding Canada’s domestic biomanufacturing sector, focusing
on both short-term strategic solutions and a long‑term vision. By
investing in this project, our government is helping to keep
expertise in Canada, creating and maintaining highly skilled jobs,
and securing the health and safety of Canadians. By fostering an
environment where companies can invest and grow, leading life
sciences firms like Sanofi are increasingly looking to this country
to establish their manufacturing facilities,”
Sanofi expects this new facility to be
operational in 2026, following design, construction, testing and
qualification of the facility and equipment.
Fluzone High-Dose Quadrivalent influenza vaccine
is currently manufactured exclusively by Sanofi Pasteur, Sanofi’s
vaccines global business unit, at its Swiftwater, Pennsylvania Site
in the United States. Sanofi Pasteur has been continuously
investing in expanding manufacturing capabilities for influenza
vaccines. Two new, additional facilities in Swiftwater, Pa., US and
Val-de-Reuil, France will start to operate in the coming years.
Editor’s Note:
This investment in a new vaccine manufacturing facility
further demonstrates Sanofi’s overall growth strategy, with
vaccines contributing as a key growth driver through differentiated
products, market expansion and new launches.
About Fluzone High-Dose Quadrivalent
influenza vaccine
Fluzone High-Dose Quadrivalent influenza vaccine
is available in the United States and some European countries, and
will be available in Canada in 2021, for use in adults 65 years and
older, and has also been approved in Australia. The vaccine has
received marketing authorizations in 25 countries in Europe (under
the name Efluelda® outside of the UK) for use in adults 60 years of
age and older. The high-dose vaccine has four times more antigen
than standard-dose vaccine and is specifically designed to provide
superior protection against influenza for older adults.ii Older
adults have an elevated risk of pneumonia, heart attack and stroke
following influenza and are at the greatest risk of
influenza-related hospitalization and death.
Sanofi Pasteur’s High-Dose influenza vaccine has
earned recommendations for use over standard-dose influenza vaccine
in individual adults 65 years and older by the National Advisory
Committee on Immunization (NACI) in Canadaiii, along with a
recommendation for priority use in people 60 years of age and
older by Germany’s Standing Committee on Vaccination (STIKO).iv
Fluzone High-Dose Trivalent influenza vaccine demonstrated superior
protection against influenza in adults aged 65 and above compared
to standard-dose formulationv.
About the Sanofi Pasteur Canadian
Facilities Founded as the Connaught Antitoxin Laboratories
and University Farm in 1917, Sanofi Pasteur's Canadian facility has
supported numerous scientific breakthroughs while making
significant public health contributions. One hundred years
ago, the Toronto Site was home to some of the initial
research for the discovery of insulin, as well as large-scale
commercial insulin production for all of Canada until the
1980s. It also produced a highly accessible antitoxin for
diphtheria, the leading public health threat to Canadian children
in the early 1900s, and was an important partner in the eradication
of polio in North America and smallpox around the world.
In 2018, Sanofi made another historic investment
at the Toronto Site, to establish one of the most advanced vaccine
bulk manufacturing facilities in the world. At the time, this was
the largest investment ever made by Sanofi globally, at
approximately €335 million. This manufacturing facility will
produce seven antigens: five-component-pertussis, plus diphtheria
and tetanus, to help meet global demand for more life-saving
vaccines for children and adults worldwide. License approval for
the United States and Canada is expected in 2024 for the
five-component-pertussis and in 2025 for diphtheria and
tetanus.
Sanofi Pasteur’s commitment to improve
influenza prevention
As the leading manufacturer of influenza
vaccines, Sanofi Pasteur is committed to researching and developing
differentiated and proven solutions to protect people of all ages
and risk groups against influenza and its complications.
During the 2020-2021 influenza season, Sanofi
Pasteur supported health authorities in efforts to strengthen
influenza vaccination campaigns in the unique context of the
COVID-19 pandemic. Sanofi Pasteur delivered 20 percent more doses
this year, reaching an unprecedented production level of 250
million doses, across its influenza vaccine portfolio. Eight
countries in Europe, and Israel, procured Fluzone High-Dose
Quadrivalent in 2020 – through special importation – to provide an
additional protection to their older citizens
Sanofi Pasteur produces influenza vaccines each
year across five international
sites: Swiftwater (Pennsylvania, United States), Pearl
River (New York, United States),
Val-de-Reuil (France), Ocoyoacac (Mexico) and
Shenzhen (China). This makes Sanofi Pasteur the largest
manufacturer of influenza vaccines in the
world.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe. Sanofi, Empowering Life |
Media Relations Contacts Ashleigh KossTel: +1
(908) 205-2572Ashleigh.Koss@sanofi.com Nicolas Kressmann
Tel.: +1 (732) 532 53-18 Nicolas.Kressmann@sanofi.com
|
Investor Relations Contacts Paris Eva
Schaefer-Jansen Arnaud DelepineYvonne Naughton
Investor Relations Contacts North America Felix
LauscherFara BerkowitzSuzanne Greco IR main line:Tel.: +33
(0)1 53 77 45 45investor.relations@sanofi.com
https://www.sanofi.com/en/investors/contact |
Sanofi Forward-Looking StatementsThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
COVID-19 will have on us, our customers, suppliers, vendors, and
other business partners, and the financial condition of any one of
them, as well as on our employees and on the global economy as a
whole. Any material effect of COVID-19 on any of the
foregoing could also adversely impact us. This situation is
changing rapidly and additional impacts may arise of which we are
not currently aware and may exacerbate other previously identified
risks. The risks and uncertainties also include the uncertainties
discussed or identified in the public filings with the SEC and the
AMF made by Sanofi, including those listed under “Risk Factors” and
“Cautionary Statement Regarding Forward-Looking Statements” in
Sanofi’s annual report on Form 20-F for the year ended December 31,
2020. Other than as required by applicable law, Sanofi does not
undertake any obligation to update or revise any forward-looking
information or statements |
i Diazgranados, C. A., et al. (2014). Efficacy of High-Dose
versus Standard-Dose influenza vaccine in older adults. New England
Journal of Medicine, 371(7), 635-645ii Diazgranados, C. A., et al.
(2014). Efficacy of High-Dose versus Standard-Dose influenza
vaccine in older adults. New England Journal of Medicine, 371(7),
635-645iii Public Health Agency of Canada (2020. An Advisory
Committee Statement (ACS) National Advisory Committee on
Immunization (NACI) Canadian Immunization Guide Chapter on
Influenza and Statement on Seasonal Influenza Vaccine for
2021–2022
iv Epidemiological Bulletin 1/2021. Decision and scientific
justification of the STIKO for the update of the
influenza vaccination recommendation for people aged ≥60 years.
Accessed March 9, 2021.
v DiazGranados CA, et al. N Engl J Med. 2014;371(7):635-645
https://www.nejm.org/doi/full/10.1056/nejmoa1315727
Sanofi (BIT:1SAN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
From Mar 2023 to Mar 2024